ACRX Share Price

Open 3.20 Change Price %
High 3.35 1 Day 0.15 4.69
Low 3.15 1 Week 0.15 4.69
Close 3.35 1 Month 0.40 13.56
Volume 820336 1 Year -0.33 -8.97
52 Week High 4.08
52 Week Low 1.95
ACRX Important Levels
Resistance 2 3.54
Resistance 1 3.46
Pivot 3.28
Support 1 3.24
Support 2 3.16
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

ACRX Technical Analysis 3
As on 22nd Sep 2017 ACRX Share Price closed @ 3.35 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.85 & Buy for SHORT-TERM with Stoploss of 3.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACRX Target for September
1st Target up-side 3.82
2nd Target up-side 4.18
3rd Target up-side 4.54
1st Target down-side 2.78
2nd Target down-side 2.42
3rd Target down-side 2.06
ACRX Other Details
Segment EQ
Market Capital 65612500.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.acelrx.com
ACRX Address
ACRX
351 Galveston Drive
Redwood City, CA 94063
United States
Phone: 650-216-3500
Fax: 650-216-6500
ACRX Latest News
Interactive Technical Analysis Chart AcelRx Pharmaceuticals, Inc. ( ACRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AcelRx Pharmaceuticals, Inc.
ACRX Business Profile
AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a development-stage company. It is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company has completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Management System, or ARX-02, for the treatment of cancer breakthrough pain (BTP), and the Sufentanil/Triazolam NanoTab, or ARX-03, designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. The Company is preparing to initiate two Phase 3 clinical trials for its product candidate, the Sufentanil NanoTab PCA System, or ARX-01. Its operations are based in Redwood City, California.